Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of TQB3525, Phosphatidylinositol-3-Kinase α and δ Inhibitors, in Patients With Advanced Bone Sarcomas

NCT04690725 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT04690725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04690725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of TQB3525, Phosphatidylinositol-3-Kinase α and δ Inhibitors, in Patients With Advanced Bone Sarcomas
Lead sponsor
Peking University People's Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 1, 2020
Completion date
June 1, 2022
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, self, safety issues